O18-6 Safety of encorafenib, binimetinib, plus cetuximab for Japanese patients with BRAF V600E metastatic colorectal cancer

Abstract

The encorafenib, binimetinib, and cetuximab (triplet) regimen showed a similar incidence of any adverse events (AEs) and grade 3 or higher AEs compared to the control regimen in the global phase III BEACON trial. However, safety profile of the triplet regimen in Japanese patients (pts) is limited due to a small number of pts enrolled to the BEACON trial. The expanded access program (EAP) was conducted to evaluate the safety and efficacy of this regimen in Japan. Herein we report safety in details and treatment status.